Condition: Advanced Malignancy · Advanced Solid Cancers · Metastatic Solid Tumors · Sponsor: Adcytherix SAS
The purpose of this first-in-human study is to explore the safety, pharmacokinetics and effects of the study drug ADCX-020 in patients with advanced and metastatic solid tumors. ADCX-020 is an investigational anticancer therapy called antibody drug conjugate. This study is set up in multiple parts. In the first part of the study, participants receive increasing doses of ADCX-020. Then 2 or more doses will be assessed to identify the optimal dose. This optimal dose is subsequently evaluated for effect on different cancer types.
This description comes directly from the study's public registry record.
Adcytherix SAS · +31 628839232 · clinicaltrials@adcytherix.com
Always discuss trial participation with your own doctor first.
| Macquarie University | Sydney, New South Wales, Australia | Recruiting |
| Blacktown Hospital | Sydney, New South Wales, Australia | Recruiting |
| Sunshine Coast University Private Hospital | Birtinya, Queensland, Australia | Recruiting |
| Tasman Oncology Research | Southport, Queensland, Australia | Recruiting |
| Cancer Research SA | Adelaide, South Australia, Australia | Recruiting |
| Linear Clinical Research | Nedlands, Western Australia, Australia | Recruiting |
| START Barcelona | Barcelona, Barcelona, Spain | Recruiting |
| START Madrid FJD | Madrid, Madrid, Spain | Recruiting |
| START Madrid CIOCC | Madrid, Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07238075